The European Directorate for the Quality of Medicines and Healthcare rates the corrective actions taken by the company on certain quality issues as appropriate. The European body had inspected the company’s Bavla site in February 2020.Dishman Carbogen Amcis expects turnaround in FY22, working on resolution of regulatory issues at Bavla site
The European Directorate for the Quality of Medicines and Healthcare rates the corrective actions taken by the company on certain quality issues as appropriate. The European body had inspected the company’s Bavla site in February 2020.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment